International In

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/42 A61K3 A61K31/435

A61K31/415

A61K31/433 A61K31/4245 A61P9/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 **A61K** 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 26212 A (MERCK PATENT GMBH ;GOODMAN SIMON (DE); MAERZ JOACHIM (DE); RADDATZ) 11 May 2000 (2000-05-11)	
Α	WO 01 83469 A (KIM EUNICE EUN KYEONG ;CHOI SEI HYUN (KR); CHUNG HYUN HO (KR); JEO) 8 November 2001 (2001-11-08)	
A	WO 02 08217 A (WATANABE YOSHIAKI ;ONO YOSHIYUKI (JP); CHUGAI PHARMACEUTICAL CO LT) 31 January 2002 (2002-01-31)	
Α	WO 96 06611 A (SMITHKLINE BEECHAM CORP ;MAYER RUTH JUDIK (US)) 7 March 1996 (1996-03-07)	
A	WO 96 40110 A (SUGEN INC) 19 December 1996 (1996-12-19)	
	-/	

Further documents are listed in the continuation of box C.	χ· α Patent family members are listed in annex:
Special categories of cited documents:  A document defining the general state of the art which is not considered to be of particular relevance  E earlier document but published on or after the international filing date  L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  O document referring to an oral disclosure, use, exhibition or other means  P document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search  16 October 2003	Date of mailing of the International search report 03/11/2003
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer Stienon, P

Internation No. PCT/Er 03/06191

		PC1/Er 03	700131
C.(Continu	ation) DOCUMENTS CONSIDERED RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
A .	LEE S. ROSEN: "Clinical experience with angiogenesis inhibitors: focus on vascular endothelial growth factor (VEGF) blockers" CANCER CONTROL, 'Online! vol. 9, no. 2, 2002, pages 36-44, XP002258080 Retrieved from the Internet: <url:http: 36.pdf="" ccj="" pdf="" pubs="" v9s2="" www.moffitt.usf.edu=""> 'retrieved on 2003-10-16! the whole document</url:http:>		
Α	BRUCE J. TERMAN AND KONSTANTIN V. STOLETOV: "VEGF AND TUMOR ANGIOGENESIS" J.BIOL.AND MED., 'Online! vol. 18, 2001, pages 59-66, XP002258150 Retrieved from the Internet: <url:http: 66.pdf="" einstein="" home="" number_2="" pdfs="" quarterly="" vegf_59-="" volume_18="" www.aecom.yu.edu=""> 'retrieved on 2003-10-16! the whole document</url:http:>		
	<del></del>		
	,		
• •	o:		<b>.</b> .
			1
	•		

inter pnal application No. CT/EP 03/06191

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:  see FURTHER INFORMATION sheet PCT/ISA/210
2	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
or <b>3.</b> , , , , , ,	As only, some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 11-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

PCT/E<sub>1</sub> 23/06191

Patent document cited in search report		ollication date		Patent family member(s)	1	Publication date
WO 0026212	A	11-05-2000	DE	19850131	A1	04-05-2000
			ΑU	754280	B2	14-11-2002
			AU	6471699	Α	22-05-2000
			BR	9914893	Α	17-07-2001
			CA	2348391	A1	11-05-2000
			CN	1329610	T	02-01-2002
			CZ	20011515	A3	15-08-2001
			WO	0026212	A1	11-05-2000
			EP	1124824	A1	22-08-2001
			HU	0104800		29-07-2002
			JP	2002528544	T	03-09-2002
			NO	20012108		27-04-2001
			PL	347246	A1	25-03-2002
			SK	5532001		03-12-2001
			ZA	200104411	Α	29-08-2002
WO 0183469	A	08-11-2001	KR	2002021848	Α	23-03-2002
			KR	2002021851	Α	23-03-2002
			AU	5509001	Α	12-11-2001
			CA	2407796	A1	08-11-2001
			CN	1433410	T	30-07-2003
			EP	1280789	A1	05-02-2003
			WO	0183469	A1	08-11-2001
			US	2003125356	A1	03-07-2003
WO 0208217	A	31-01-2002	AU	7898001	Α	05-02-2002
			MO	0208217	A2	31-01-2002
WO 9606611	Α	07-03-1996	WO	9606611	A1	07-03-1996
WO 9640110	A	19-12-1996	US	5763470	Α	09-06-1998
			ΑU	5886196	Α	30-12-1996
			CA	2224100	A1	19-12-1996
			EP	0833630	A1	08-04-1998
			JP	11507042	T	22-06-1999
			WO	9640110	A1	19-12-1996